Generic abilify maintena availability?

When will generic Abilify Maintena be available?

Generic Abilify Maintena, the injectable form of the antipsychotic medication aripiprazole, has been a topic of interest among healthcare professionals and patients. [1] Currently, the injectable form of Abilify Maintena is sold under a patent that restricts generic production until 2026. [2]

Who can provide generic Abilify Maintena before patent expiry?

Biosimilars, or highly similar versions of a medication, can enter the market sooner than generics. However, the development and FDA approval process for biosimilars may still take a few years to complete. [3] Companies interested in developing generic or biosimilar versions of Abilify Maintena, such as Teva and Sandoz, are already working on their offerings. [4]

What does the patent expiry mean for patients?

The patent expiry in 2026 indicates that, once the patent has expired, other companies may be able to produce and sell generic versions of Abilify Maintena, potentially reducing costs for patients. This could lead to more affordable treatment options for patients requiring the medication. [5] Patients should consult their healthcare provider to discuss potential alternatives and the latest on generic Abilify Maintena development.

Sources:

[1] - https://www.drugpatentwatch.com/
[2] - https://www.drugpatentwatch.com/dru ...
[3] - https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC7057301/
[4] - https://www.tevapharm.com/press- releases/pharmaceuticals/teva-ann ... - sandoz/
[5] - https://www.drugpatentwatch.com/s ...